39.65 +0.03 (0.08%)
Pre-Market: 8:41AM EDT
|Bid||39.52 x 800|
|Ask||39.69 x 4000|
|Day's Range||39.17 - 39.83|
|52 Week Range||34.37 - 46.47|
|Beta (3Y Monthly)||0.59|
|PE Ratio (TTM)||21.23|
|Forward Dividend & Yield||1.44 (3.39%)|
|1y Target Est||N/A|
The board of directors of Pfizer Inc. today declared a 36-cent second-quarter 2019 dividend on the company’s common stock, payable June 7, 2019 to shareholders of record at the close of business on May 10, 2019. The second-quarter 2019 cash dividend will be the 322nd consecutive quarterly dividend paid by Pfizer. “In 2018, we estimate that we reached more than 784 million people with our products,” stated Albert Bourla, Pfizer Chief Executive Officer.
Pfizer Inc. (PFE) and Eli Lilly and Company (LLY) today announced top-line results from a Phase 3 study evaluating tanezumab 2.5 mg and 5 mg. The objective of the study was to compare the long-term joint safety and 16-week efficacy of tanezumab relative to nonsteroidal anti-inflammatory drugs (NSAIDs) in patients with moderate-to-severe osteoarthritis (OA) of the hip or knee. The tanezumab 5 mg treatment arm met two of the three co-primary efficacy endpoints, demonstrating a statistically significant improvement in pain and physical function compared to NSAIDs at the 16-week analysis, while patients’ overall assessment of their OA was not statistically different than NSAIDs. Patients who received tanezumab 2.5 mg did not experience a statistically significant improvement in pain, physical function or patients’ overall assessment of their OA at 16 weeks compared to NSAIDs.
Pfizer Inc. invites investors and the general public to listen to an audio webcast of the Annual Meeting of Shareholders at 9:00 a.m. Eastern Daylight Time on Thursday, April 25, 2019. To pre-register and access the live audio webcast, visit https://investors.pfizer.com/proxy and click on the “Meeting Webcast” button. At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives.
The U.S. FDA awarded Breakthrough Therapy Designation for this potential indication based on these Phase 2 data
Approval of expanded indication based predominately on real-world data
AM Best has affirmed the Financial Strength Rating of A (Excellent) and the Long-Term Issuer Credit Rating of “a+” of Blue Whale Re Ltd. (Blue Whale) (Burlington, VT). The outlook of these Credit Ratings (ratings) is stable. The ratings reflect Blue Whale’s balance sheet strength, which AM Best categorizes as very strong, as well as its strong operating performance, neutral business profile and appropriate enterprise risk management (ERM).
Pfizer Inc. today announced that the European Commission has approved VIZIMPRO® , a tyrosine kinase inhibitor , as monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor -activating mutations.
BRISBANE, Calif. and NEW YORK, April 2, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (SGMO), a genomic medicine company, and Pfizer, Inc. (PFE) today announced interim data from the Phase 1/2 Alta study evaluating investigational SB-525 gene therapy for severe hemophilia A. Data indicate that SB-525 was generally well-tolerated and demonstrated a dose-dependent increase in Factor VIII (FVIII) levels across the four dosage cohorts. Eight patients total were dosed.
Sangamo Therapeutics, Inc. (SGMO), a genomic medicine company, and Pfizer, Inc. (PFE) today announced interim data from the Phase 1/2 Alta study evaluating investigational SB-525 gene therapy for severe hemophilia A. Data indicate that SB-525 was generally well-tolerated and demonstrated a dose-dependent increase in Factor VIII (FVIII) levels across the four dosage cohorts. Eight patients total were dosed.
- Q4 share repurchases increased 62.8% year-over-year to a record $223.0 billion - This is the fourth consecutive quarterly record -- longest streak in the 20 years SPDJI has tracked - Total 2018 buybacks ...
Vivet Therapeutics (“Vivet”), a privately held gene therapy biotech company dedicated to developing gene therapy treatments for inherited liver disorders with high unmet medical need, and Pfizer Inc. (PFE) announced today that Pfizer has acquired a 15% equity interest in Vivet and secured an exclusive option to acquire all outstanding shares. Pfizer and Vivet will collaborate on the development of VTX-801, Vivet’s proprietary treatment for Wilson disease.
DARMSTADT, Germany and NEW YORK , March 19, 2019 /PRNewswire/ -- Not intended for UK-based media Merck KGaA, Darmstadt, Germany , which operates its biopharmaceutical business as EMD Serono in the US and ...
Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, April 30, 2019. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s First Quarter 2019 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors.
AUGUSTUS is the largest trial in this high-risk patient population requiring both anticoagulant and antiplatelet therapies
Pfizer Inc. today announced the United States Food and Drug Administration has approved TRAZIMERA™ , a biosimilar to Herceptin® (trastuzu
CAMBRIDGE, Mass., March 5, 2019 /PRNewswire/ -- AnTolRx, Inc., a private biotechnology company and a leader in immune tolerance, today announced that Pfizer Inc. (PFE) has exercised the option granted under a June 2016 agreement to license an immune tolerance therapy from AnTolRx's Type 1 diabetes research program. The option gives Pfizer exclusive rights to pursue development of AnTolRx's lead immunotherapeutic for Type 1 diabetes. Pfizer will be responsible for any further optimization, development and potential commercialization.
Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Andy Schmeltz, Global President, Oncology, and Chris Boshoff, Chief Development Officer, Oncology, at the Cowen and Company 39th Annual Healthcare Conference on Tuesday, March 12, 2019 at 9:20 a.m. Eastern Daylight Time.
Pfizer intends to use the net proceeds for general corporate purposes, including to refinance, redeem or repurchase existing debt and to repay a portion of its outstanding commercial paper. Barclays Capital Inc., Deutsche Bank Securities Inc., Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC are acting as joint book-running managers for the offering.
NEW YORK, March 04, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
Clinical partnership to evaluate triple combination of BioXcel Therapeutics’ BXCL701, Nektar’s NKTR-214 and avelumab (Merck KGaA, Darmstadt, Germany and Pfizer) in pancreatic.
Pfizer today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for LORVIQUA® , an anaplastic lymphoma kinase tyrosine kinase inhibitor .
Company also provides update on upcoming presentation from a Phase 2 proof-of-concept study and Phase 3 pivotal trial status
HENDERSON, NV / ACCESSWIRE / February 25, 2019 / The cost of healthcare has been outpacing inflation. According to Investor's Business Daily, the U.S. soon will ''spend nearly 20% of its gross domestic ...
Ochsner Health System, Louisiana’s largest non-profit academic healthcare system, and Pfizer Inc (PFE) have entered into a multi-year strategic alliance to develop innovative models for clinical trials. Through this partnership, Pfizer and Ochsner — through its innovation lab, innovationOchsner (iO), in partnership with Ochsner Research — will explore ways to enhance the clinical trial experience and ease participation in clinical research for both patients and healthcare professionals. The alliance aims to create faster, improved access and connectivity to clinical trials for patients, with the ultimate goal of better experiences and outcomes.
“Pfizer is dedicated to increasing access to biosimilars for patients suffering from serious illnesses and helping create a more sustainable healthcare system,” said Andreas Penk, M.D., regional president, Oncology International Developed Markets at Pfizer.